Buradasınız

Anasayfa » Content

Benign prostat hiperplazisi düşük ve yüksek dereceli PIN ve prostat adenokarsinomu olarak CD24 ekspresyonu

CD24 expression in benign prostate hyperplasia low and high grade PIN and prostate adenocarcinoma

Journal Name:

  • Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2010

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Purpose: CD24 recently identified novel prognostic marker gene that functions as an alternative ligand of P-selectin, an adhesion receptor expressed on activated endothelial cells and platelets. It has been implicated in metastatic tumor progression of various solid tumors. We aimed to investigate CD24 expression in prostate adenocarcinomas, low and high grade prostatic intraepithelial neoplasias (PINs) and benign prostate hyperplasias (BPHs), and to evaluate its relationship with histopathological parameters, and serum PSA level. Material and Methods: We examined immunohistochemically the expression of CD24 protein in 76 prostate adenocarcinomas, 16 low grade PIN, 16 high grade PIN, and 14 BPH and correlated our findings with histopathological parameters, and serum PSA level. Results: While we detected CD24 expression in prostat adenocarcinomas and PIN specimens, there was no expression in benign prostate tissues. CD24 immunoreactivity was detected in 48 (63.2%) out of 76 prostate adenocarcinomas. Expression of CD24 was significantly higher in prostate adenocarcinoma and high grade PIN compared with BPH (p=0,000, p=0,040 ) In prostate adenocarcinomas cytoplasmic CD24 expression was significantly positively correlated with Gleason score (p=0.000, r= 0.465) and PSA level (p=0.022, r=0.263). Conclusions: Our findings demonstrated that positive CD24 expression occurs in prostate adenocarcinomas with high Gleason score, and high PSA level. We suggest that CD24 might constitute an important moleculer marker for prostate cancer.
Bookmark/Search this post with
Abstract (Original Language): 
Amaç: CD24 aktive endotel hücreleri ve trombositler üzerinde eksprese edilen bir adezyon reseptörü olan P-selektin'in alternatif ligandı olarak fonksiyon gören son zamanlarda tanımlanan yeni bir prognostik belirleyici gendir. CD24'ün çeşitli solid tümörlerin metastatik tümör gelişiminde rol oynadığı düşünülmektedir. Çalışmamızda prostat adenokarsinomlarında, düşük ve yüksek dereceli prostat intraepitelyal neoplazilerde (PIN) ve benign prostat hiperplazisinde (BPH) CD24 ekspresyonunun histopatolojik parametreler ve serum PSA seviyesi ile ilişkisini değerlendirmeyi amaçladık. Gereç ve Yöntem: Yetmişaltı prostat adenokarsinomu, 16 düşük dereceli PIN, 16 yüksek dereceli PIN ve 14 BPH vakasında immunohistokimyasal olarak CD24 ekspresyonunu inceleyerek bulgularımızın histopatolojik parametreler ve serum PSA seviyesi ile ilişkisini değerlendirdik. Bulgular: Prostat adenokarsinomu ve PIN materyallerinde CD24 ekspesyonu saptanırken benign prostat dokularında ekspresyon izlenmedi. 76 prostat adenokarsinomu olgusunun 48'inde (%63.2) CD24 immunoreaktivitesi saptandı. CD24 ekspresyonu prostat adenokarsinomu ve yüksek dereceli PIN gruplarında BPH grubu ie karşılaştırıldığında anlamlı şekilde yüksek bulundu (p=0,000, p=0,040 ). Prostat adenokarsinomunda sitoplazmik CD24 ekspresyonu Gleason skoru (p=0.000, r= 0.465) ve PSA seviyesi (p=0.022, r=0.263) ile anlamlı şekilde pozitif korele bulundu. Sonuçlar: Bulgularımız prostat adenokarsinomlarında pozitif CD24 ekspresyonunun yüksek Gleason skoru ve yüksek PSA seviyesi ile birlikteliğini gösterdi. CD24'ün prostat kanseri için önemli bir moleküler belirleyici olabileceği kanısındayız.
FULL TEXT (PDF): 
PDF icon arastirmax-benign-prostat-hiperplazisi-dusuk-yuksek-dereceli-pin-prostat-adenokarsinomu-olarak-cd24-ekspresyonu.pdf
  • 2
14-18
  • Turkish

REFERENCES

References: 

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics 2007. CA Cancer J Clin 2007;57:43-66.
2. May F, Hartung R, Breul J. The ability ofthe American Joint Committee on Cancer Staging system to predict progression-free survival after radical prostatectomy. BJUInt2001; 88(7):702-7
3. Fischer GF, Majdic O, Gadd S, Knapp W. Signal transduction in lymphocytic and myeloid cells via CD24 a new member of phosphoinositol-anchored membrane molecules. J Immunol 1990;144:638-641
4. Pirruccello SJ, LeBien TW. The human B-cell associated antigen CD24 is a single chain sialoglycoprotein. J Immunol 1986:136: 3779-3784
5- Kristiansen G, Sammar M, Altevogt P. Tumour biological aspects of CD24, a mucin-like adhesion molecule. J Mol Histol 2004;35: 255-262
6. Nestl A, Von Stein OD, Zatloukal K, Thies WG, Herrlich P, Hofmann M et al. Gene expression patterns associated with the metastatic phenotype in rodent and
human tumors. Cancer Res 2001;61:1569-1577
7. Jackson D, Waibel R, Weber E, Bell J, Stahel RA. CD24, a signal-transducing molecule expressed on human B cells, is a major surface antigen on small cell lung carcinomas. Cancer Res 1992;52: 5264-5270
8. Fogel M, Friederichs J, Zeller Y, Husar M, Smirnov A, Roitman L et al. CD24 is a marker for human breast carcinoma. Cancer Lett 1999;143:87-94
9. Kristiansen G, Pilarsky C, Pervan J, Stürzebecher B, Stephan C, Jung K et al. CD24 expression is a significant predictor ofPSA relapse and poor prognosis in low grade or organ confined prostate cancer. Prostate 2004;58:183-192
10. Kristiansen G, Denkert C, Schlüns K, Dahl E, Pilarsky C, Hauptmann S. CD24 is expressed in ovarian cancer and is a new independent prognostic marker ofpatient survival. Am J Pathol 2002;161:1215-1221
11. Aigner S, Ruppert M, Hubbe M, Sammar M, Sthoeger Z, Butcher EC et al. Heat stable antigen (mouse CD24) supports myeloid cell binding to endothelial and platelet P-selectin. Int Immunol 1995;7:1557-1565
12. Aigner S, Sthoeger ZM, Fogel M, Weber E, Zarn J, Ruppert M et al. CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells. Blood 1997;89:3385-3395
13. Epstein JI, Algaba F, Alsbrook WC. Tumours ofthe prostate. In: Eble JN, Sauter G, Epstein JI, Sesterhenn IA. Pathology and Genetics ofTumours ofthe Urinary System and Male Genital Organs. Lyon, IARC Press,2004: 160
14. Baumann P, Cremers N, Kroese F, Orend G, Chiquet-Ehrismann R, Uede T et al. CD24 expression causes the acquisition ofmultiple cellular properties associated with tumor growth and metastasis. 2005;65(23):10783-
93
15. The metastasis-associated gene CD24 is regulated by Ral GTPase and is a mediator ofcell proliferation and survivalinhumancancer. CancerRes. 2006;66(4):1917-
22
16. Analysis ofgene expression identifies candidate markers and pharmacological targets in prostate cancer.Cancer Res. 2001;61(16):5974-8
17. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C et al. Gene expression correlates of clinical prostate cancer behavior. 2002;1(2):203-9
18. Lim SC. CD24 and human carcinoma: tumor biological aspects. 2005;59(2):351-4
19. Weichert W, Denkert C, Burkhardt M, Gansukh T, Bellach J, Altevogt P et al. Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival. Clin Cancer Res 2005;11(18):6574-6581

Thank you for copying data from http://www.arastirmax.com